Physician profile

Yaqub Ali

Knoxville, TN

NPI 1801893771

$566.46

in general payments reported to CMS, 2019-2025

6 companies · $22.41 in 2025

The $22.41 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$405.78
Education$45.65

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nxstage Medical, INC. $244.04 2022-2024
Ardelyx, INC. $121.82 2024 Xphozah 30 Mg
Novo Nordisk INC $111.56 2024
Akebia Therapeutics INC $45.59 2024 Vafseo, Auryxia
La Jolla Pharmaceutical Company $22.41 2025 Giapreza
Travere Therapeutics, INC. $21.04 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Yaqub Ali

$566.46

in general payments reported 2019-2025

Years
2022-2025
Top company
Nxstage Medical, INC.
Context
The $22.41 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/1302470/yaqub-ali

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.